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Abstract 
Nanocrystal budesonide (nanobudesonide) is a suspension for nebulization in patients with 
steroid-responsive pulmonary disease such as asthma.  The pharmacokinetics and safety of 
the product were compared to those of Pulmicort® Respules™.  Sixteen healthy volunteers 
were administered nanobudesonide 0.5 and 1.0 mg, Pulmicort® Respules™ 0.5 mg and 
placebo in a four-way, randomized crossover design.  All nebulized formulations were 
well-tolerated, with no evidence of bronchospasm.  Nebulization times were significantly 
shorter for nanobudesonide compared to Pulmicort® Respules™.  Because of a low oral 
bioavailability, plasma concentration of budesonide is a good marker of lung-delivered 
dose.  The pharmacokinetics of nanobudesonide 0.5 and 1.0 mg were approximately dose 
proportional with respect to Cmax, AUC(0-t), and AUC(0-inf).  Nanobudesonide 0.5 mg and 
Pulmicort® Respules™ 0.5 mg exhibited similar AUC’s, suggesting a similar extent of 
pulmonary absorption.  A higher Cmax was noted with nanobudesonide 0.5 mg and the Tmax 
was significantly different, suggesting a more rapid rate of drug delivery of 
nanobudesonide 0.5 than Pulmicort® Respules™.  In conclusion, nebulized 
nanobudesonide 0.5 mg was safe in healthy volunteers, with a similar extent of absorption 
as Pulmicort Respules.   
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Inhaled anti-inflammatory corticosteroid therapy is an important component of the 
treatment regimen for chronic asthma.  Practice guidelines recommend their use as first-
line therapy for all cases of asthma, except mild intermittent asthma1,2.  The use of inhaled 
steroids early in the course of the disease is associated with improved outcomes compared 
to treatment with beta 2 adrenergic agonists.3  Indeed, the early use of inhaled 
corticosteroids may alter the natural history of the disease4, and possibly reduce the 
irreversible airway obstruction associated with chronic inflammation of the lungs5. 
Budesonide is a potent anti-inflammatory corticosteroid with low oral bioavailability.  It 
forms reversible intracellular fatty acid esters in airway and lung tissue, which may prolong 
lung retention.6  Budesonide is available as a dry powder inhaler (DPI) and as PulmicortR 
RespulesTM (AstraZeneca, Wilmington, DE), a suspension for inhalation with a jet-air 
table-top nebulizer.  Pulmicort® Respules™ is the only corticosteroid suspension for 
inhalation available in the United States.  The DPI form of inhalation therapy is often 
limited by difficulty with coordination of inspiration, especially in pediatric patients.  In 
addition, the DPI’s require adequate inspiratory flow for drug delivery.  For these reasons, 
budesonide delivered by a table-top nebulizer has found increasing use as the best 
alternative for delivery of corticosteroids to the lungs in children. 
Nanobudesonide is a new formulation of budesonide that has been developed for use in a 
table-top nebulizer.  Suspended drug particles (the disperse phase) are in the 75-300 
nanometer range in this formulation.  This compares to particle size of 4,400 nanometer 
for Pulmicort® RespulesTM.7  The small crystal size of budesonide in the nanocrystal 
formulation gives the suspension solution-like characteristics, which may shorten delivery 
time and improve intrapulmonary distribution compared to the existing preparation.  In this 
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study, the safety, delivery, and pharmacokinetics of nebulized nanobudesonide were 
compared to Pulmicort® RespulesTM. 
METHODS 
Subjects 
Sixteen healthy volunteers (13 males and 3 females) with a mean age of 32.5 (range 25-
40), mean height of 171.0  8.4 cm, and mean weight 76.8  14.5 kg participated in this 
study.  The study was approved by the Institutional Review Board of Thomas Jefferson 
University in Philadelphia, PA.  All subjects gave written informed consent to participate 
prior to undergoing any study procedures.  No study subject used a topical or systemic 
corticosteroid, or ingested a cytochrome P4503A inhibitor within 4 weeks of study 
initiation.  Subjects with a history of bronchospasm or a screening FEV1/FVC of <80% of 
predicted were excluded from participation. 
Study Design 
This was a randomized, double-blind, four-arm, single-dose cross-over study that 
compared the pharmacokinetics and safety of nanobudesonide and Pulmicort® RespulesTM.  
The four study arms were (1) placebo, (2) 0.5 mg of PulmicortR RespulesTM, (3) 0.5 mg of 
nanobudesonide and (4) 1.0 mg of nanobudesonide.  Healthy volunteers were admitted to 
the Clinical Pharmacology Research Unit of Thomas Jefferson Hospital the day before 
each treatment.  Following an overnight fast, they received one of the four randomized 
treatments.  The study protocol specified that each subject was to receive treatments not 
less than 5 or more than 10 days apart. 
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Spirometry, oximetry, clinical laboratory tests, ECG and vital signs were performed at 
baseline and at specified intervals.  The spirometer was calibrated on a daily basis.  Adverse 
events were monitored throughout the study.  Twenty-four hours after each treatment, 
subjects were reevaluated and discharged from the unit.  
Test Drugs and Administration 
Nanobudesonide and placebo were manufactured by Automated Liquid Packaging, 
(Woodstock, IL) using plastic blow/fill/seal ampules.  Packaging and labeling were 
performed by PCI Services - Clinical Services (Philadelphia, PA).  The nanobudesonide 
placebo consisted of the same ingredients as nanobudesonide without the budesonide.  
Pulmicort® RespulesTM were purchased from a commercial source.  Nebulizers were filled 
by an unblinded investigational pharmacist.  The fill volume for all treatments was 4.0 ml.  
For the 0.5 mg nanobudesonide treatment arm, 2.0 ml of placebo was added to 2.0 ml of 
active drug. 
All treatments were administered by nebulization with a Pari LC Jet nebulizer and a Pari 
LC Ultra compressor (PARI Respiratory Equipment, Inc., Monterey, CA).  A new 
nebulizer was used for each treatment and each subject had all four treatments administered 
with the same compressor.  Compressors were checked with a calibration nebulizer each 
day of use.  Research personnel reviewed the inhalation procedure with each subject prior 
to each treatment using a training nebulizer.  Subjects were in a sitting position and trained 
to inhale slowly and steadily through a mouthpiece with a target respiratory rate of 14 to 
20 breaths per minute.  Nose clips were utilized to avoid inspiration/expiration through the 
nose.  Nebulization was continued until one minute after sputtering was heard.  The 
duration of nebulization and the residual volumes were measured. 
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Pharmacokinetics 
Blood was drawn for budesonide levels pre-dose, at 5, 10, 15, 20, 25, 30, 40, and 60 min, 
and 2, 3, 4, 6, 8, and 24 h post-dose.  Time zero was the beginning of nebulization.  Samples 
were collected in tubes containing sodium heparin, immediately placed on ice, spun at 2200 
g for 10 min. 
Analysis of plasma samples was performed by Analytical BioChemistry Laboratories 
(Columbia, MO) utilizing a validated HPLC-MS/MS method.  Using nominal standard 
concentrations of 60.1 pg/mL and 802 pg/mL, precision for this assay was  12.9% and  
4.7% CV respectively, while accuracy was -8.6 to -2.8% RE of nominal standard 
concentrations.  Plasma was assayed for budesonide in 1.0 ml aliquots.  Samples were 
extracted on a 96-well C-18 SPE plates on a Tomtec Quadra 96 model 320.  Desonide 
(11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione) 30-1,000 pg/ml was used as an 
internal standard.  During validation, the correlation coefficient (r) was  0.9976. 
Statistical Analyses 
Statistical analyses were performed using SAS® Version 6.12  (SAS Institute, Cary, NC).  
Safety variables of FEV1, adverse events and vital signs were analyzed with an analysis of 
covariance at each time point.  Clinical laboratory measurements and oximetry were 
evaluated in each subject.  The pharmacokinetic analyses were performed with SAS using 
the sorting procedure, PROC GLM, PROC MEANS and G-PLOT.  The slope of the 
terminal phase was used to estimate AUC(0–inf).  Analysis of variance (ANOVA) was 
performed on untransformed and log transformed AUC and Cmax parameters.  The model 
included subject, period, and treatment.  For the log transformed analysis adjusted means 
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and confidence intervals were calculated for AUC(0-t), AUC (0-inf), Tmax and Cmax and back-
transformed to the arithmetic scale.  For untransformed data, treatments were compared for 
the 95% confidence intervals for the difference between means.  For transformed data, a 
95% confidence interval was calculated for the ratio of two means.  Subjects were 
evaluated on an intent-to-treat basis, and those receiving at least one dose of the trial 
medication were included in analyses.  
RESULTS 
Demographics 
Sixteen subjects were enrolled and all completed the study.  One subject exceeded the 
maximum ten day window permitted between treatment arm 3 and 4 by four days.  This 
protocol variance did not jeopardize study integrity and this subject was included in the 
analysis. 
Pharmacokinetics 
This study compared the pharmacokinetics of Pulmicort® and nanobudesonide delivered 
by inhalation (Table 1).  Because of the rapid absorption and the limited number of time 
points during the first 10 min after the initiation of inhalation, Tmax values obtained are 
considered estimates.  Nevertheless, pairwise comparisons between Pulmicort® RespulesTM 
and nanobudesonide 0.5 mg revealed significant Tmax (p=0.001) differences between 
treatments.  Indeed, maximum concentrations were achieved sooner in the nanobudesonide 
0.5 mg treatment compared to Pulmicort®.  In addition, pairwise comparisons of the log 
transformed data revealed that the Cmax for nanobudesonide 0.5 mg was significantly 
(p<0.001) higher than for a comparable dose of Pulmicort® RespulesTM.  The extent of 
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absorption of Pulmicort® RespulesTM 0.5 mg and nanobudesonide 0.5 mg, estimated by 
AUC(0-t) and AUC(0-inf), was comparable, though formal bioequivalence testing was not 
performed.  The pharmacokinetics of nanobudesonide 0.5 mg and 1.0 mg were 
approximately dose proportional with respect to Cmax, AUC(0-t), and AUC(0-inf). 
Nebulization Times and Residual Volumes 
Nebulization was continued until 1 min after sputtering, which was not detected in one 
subject receiving Pulmicort® RespulesTM and one receiving 0.5 mg of nanobudesonide 
(Table 2).  The nebulization times for these subjects were 15 and 16 min, respectively.  
Nebulization times ranged from 4.0 to 16.0 min across all treatments and mean nebulization 
times were 8.7 min for Pulmicort® RespulesTM, 7.1 min for nanobudesonide 0.5 mg, and 
7.0 min for nanobudesonide1.0 mg.  The mean nebulization time for the subjects receiving 
Pulmicort® RespulesTM was significantly longer compared to that of the nanobudesonide 
0.5 mg group (p=0.027) and the nanobudesonide 1.0 mg group (p=0.029).  There were 5, 
3 and 2 subjects with nebulization times greater than 10 min in the Pulmicort® RespulesTM, 
nanobudesonide 0.5mg and nanobudesonide 1.0 mg groups, respectively. 
Seven subjects had residual volumes greater than 1.0 ml; 4 in the Pulmicort® RespulesTM 
group, 2 in the nanobudesonide 0.5 mg group, 1 in the nanobudesonide 1.0 mg group, and 
one in the placebo group.  There was no clear relationship between higher residual volumes 
and longer nebulization times.  Three subjects had residual volumes greater than 1.0 ml in 
more than one crossover treatment period. 
Safety 
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There were no significant adverse effects associated with the administration of the test 
drugs.  Four subjects reported a total of 8 adverse events after dosing with placebo.  Two 
subjects reported a total of 4 adverse events (nausea, dizziness, paresthesia, and rhinitis) 
after dosing with Pulmicort® RespulesTM.  One adverse event was reported with each of the 
nanobudesonide groups.  These included rhinitis (nanobudesonide 0.5 mg) and edema at a 
venipuncture site (nanobudesonide 1.0 mg).  All adverse effects were classified as mild.  
There was no evidence of bronchospasm in any of the treatment arms.  For FEV1, the 
overall treatment effect was not significant at any evaluation (p0.111).  In addition, there 
were no clinically significant abnormalities in measured vital signs, pulse oximetry, 
electrocardiograms, or clinical laboratory tests. 
DISCUSSION 
Inhaled steroids are the preferred anti-inflammatory therapy in the treatment of asthma.  
Budesonide delivered by nebulization is effective in controlling pediatric asthma, as 
measured using multiple clinical endpoints.8,9,10,11  The efficacy of inhaled budesonide is 
predominantly mediated by local action, with systemic absorption contributing little, if 
anything, to the control of inflammation in the lungs.12  Budesonide has an excellent safety 
profile in children.  Pediatric patients administered chronic inhaled steroids grow to a 
normal adult height.13  However, safety concerns of a transient, decreased growth velocity 
in children14 have resulted in under-utilization of inhaled corticosteroids in this age group.15  
The goal of the new nanocrystal formulation budesonide is to maximize efficiency of 
pulmonary delivery of drug, which may serve to obviate some of these safety concerns. 
The delivery of budesonide by nebulization is a complex process that is affected by the 
characteristics of the nebulizer and compressor, droplet size, properties of the formulation, 
 10 
breathing pattern of the patient, and respiratory tree anatomy.  A small component of the 
orally deposited drug may be absorbed through the buccal mucosa.  This was minimized 
in the present study by the use of a mouthwash after nebulization.  There is little or no 
metabolism of budesonide in the lung.16  There is extensive hepatic first-pass metabolism 
of swallowed budesonide, with an oral bioavailability of ~11%.17  Pharmacokinetic 
evaluation of drug absorption from the lungs, therefore, provides an accurate and 
reproducible method for comparing the dose delivered to the lung by different inhaler 
systems or different formulations from the same inhaler system.18,19  A Medline search for 
published reports of the pharmacokinetics of budesonide suspension delivered by a table-
top nebulizer yielded a single report from a study in 10 children.20  However, neither the 
budesonide particle size in the suspension nor the manufacturer of the suspension is 
specified in this European study.  Data on file with AstraZeneca reports that in children 
with asthma, the Pari LC Jet Plus nebulizer with the Pari Master compressor delivered 
approximately 25% of labeled budesonide to the patient.21  This delivered dose was 
comparable to that in healthy adults. 
In this study of healthy volunteers, the 0.5 mg nanobudesonide and the 0.5 mg Pulmicort® 
Respules™ formulations produce a comparable budesonide AUC in plasma, indicating a 
similar extent of absorption.  Because the oral bioavailability of budesonide is relatively 
low, it is likely that this observation reflects comparable pulmonary deposition for each 
formulation.  The nanobudesonide formulation exhibited approximate linear 
pharmacokinetics between the 0.5 and 1.0 mg formulations.  The nebulization times of 
nanobudesonide 0.5 and 1.0 mg nanobudesonide were significantly shorter than those 
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observed with Pulmicort® Respules™.  There were no significant adverse effects 
associated with the delivery of the nanobudesonide formulation. 
The comparable AUC, higher Cmax and lower Tmax of 0.5 mg nanobudesonide compared to 
0.5 mg Pulmicort® Respules™ suggests more rapid drug delivery, or more rapid 
absorption.  If these differences are due to more rapid absorption, two mechanisms are 
possible.  Nanobudesonide could have more rapid dissolution of the in the airways, or a 
more distal delivery of drug may facilitate rapid absorption.  However, the PK data 
presented do not allow discrimination between these possibilities.  Drug distribution 
studies will be required to determine the degree and kinetics of pulmonary deposition.  
While some observations suggest that improved antiinflammatory drug distribution to 
small airways might result in increased clinical efficacy,22 there is no clinical proof that 
this is the case.23  Finally, results reported here in healthy adults should be extrapolated to 
other populations with caution.  Budesonide clearance20 and lung deposition19,24 differ in 
pediatric and adult populations.  Additionally, drug delivery to the lungs will differ in 
asthmatic and healthy lungs.25  The subjects in this study were not balanced with regard to 
gender and no subgroup analysis was performed owing to the small number (3) of females 
participating.  However, no gender differences are present in the pharmacokinetic 
parameters of Pulmicort® Respules™.21  The potential for differential regional lung 
delivery of inhaled nanobudesonide based upon gender is unknown.26 
In conclusion, nanobudesonide exhibited pharmacokinetics that were dose-proportional, 
and nanobudesonide 0.5 mg yielded budesonide absorption that was comparable to 
Pulmicort® Respules™.  The higher Cmax and lower Tmax of 0.5 mg nanobudesonide 
suggests a more rapid rate of either drug delivery or absorption compared to Pulmicort® 
 12 
Respules™.  In addition, nanobudesonide administration demonstrated a safety profile that 
was comparable to Pulmicort® Respules™.  The significantly shorter nebulization time 
with nanobudesonide compared to Pulmicort® Respules™ should be advantageous with 
respect to patient compliance. 
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Table 1 
 
Pharmacokinetics of Pulmicort and Nanobudesonide 
 
 
 Pulmicort  (0.5 mg) Nanobudesonide  (0.5 mg) Nanobudesonide  (1.0 mg) 
PK Parameter Mean (95% CI)  Mean (95% CI) Mean (95% CI) 
Tmax (min) 14.4 (11.4 –  18.0) 8.4 (5.4- 10.8) 11.4 (6.0- 16.2) 
Cmax (pg/mL) 662 (416- 908) 1212 (751- 1674)  2484 1236- 3733) 
AUC(0-t) 
(pg∙hr/mL) 
1518 (1071- 1966) 1472 (1171- 1773) 2725 (1981- 3469) 
AUC(0-inf) 
(pg∙hr/mL) 
1631 (1125- 2137) 1658 (1284- 2031) 2893 (2118- 3668) 
T1/2 (hr) 5.42 6.62 5.46 
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Table 2 
 
Mean Pulmicort and Nanobudesonide Nebulization Times 
 
 Duration (min) SD Range 
Placebo 6.56 1.75 5-10 
Pulmicort® Respules™ (0.5 mg) 8.70 3.38 5-16 
Nanobudesonide (0.5 mg) 7.06 3.11 5-16 
Nanobudesonide (1.0 mg) 6.95 2.48 4-13 
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Figure.  Time course of mean budesonide concentrations in plasma following oral administration of nanocrystal budesonide 
0.5 mg (circles), nanocrystal budesonide 1.0 mg (squares), and Pulmicort® Respules™ 0.5 mg (+). 
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